Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02889003 | Second STOP After Pioglitazone Priming in CML Patients(PIO2STOP) | recruiting | Phase 2 | 26 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03501576 | Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma | recruiting | — | 200 | Emory UniversityOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04877522 |
| Asciminib Roll-over Study |
| recruiting |
| Phase 4 |
| 347 |
| Novartis PharmaceuticalsINDUSTRY |
| 29 |
| Jul 6, 2026 |
| clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06697600 | A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers(UR-GOAL RCT) | recruiting | N/A | 1,020 | University of RochesterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07019155 | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants | recruiting | — | 510 | National Cancer Institute (NCI)NIH | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07325305 | Physical Activity and Exercise During Early Treatment Phases for Childhood Acute Lymphoblastic Leukaemia to Protect Against Muscle Loss and Improve Frailty Outcomes(PROTECT) | recruiting | N/A | 60 | Murdoch Childrens Research InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07548983 | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation | recruiting | Phase 1 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07684131 | EWALL-PH OBSERVARTORY 2022(Ewall Obs 2022) | recruiting | — | 100 | Versailles HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02560883 | Hairy Cell Leukemia Patient Data Registry(HCL-PDR) | recruiting | — | 5,000 | Ohio State University Comprehensive Cancer CenterOTHER | 3 | Jul 2, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT06234904 | Study of IBR733 Cell Injection in Acute Myeloid Leukemia | recruiting | Phase 1 | 18 | Imbioray (Hangzhou) Biomedicine Co., Ltd.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | recruiting | Phase 2 | 28 | University of California, DavisOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07680868 | Caris Chromoseq Data Collection | recruiting | — | 300 | Caris Science, Inc.INDUSTRY | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04050280 | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | recruiting | Phase 2 | 39 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04256018 | Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome | recruiting | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04411043 | Observatory of Prolymphocytic Leukemia T(T-PLL) | recruiting | — | 50 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06860880 | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program | recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06996119 | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant | recruiting | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07292272 | Halt Aging in Survivors of Blood Cancers(HALTAging-1) | recruiting | N/A | 180 | University of NebraskaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677878 | Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL | recruiting | Phase 1 | 60 | Liping DouOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03932903 | Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia | recruiting | N/A | 60 | Northwestern UniversityOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06357182 | Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | OHSU Knight Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01137825 | Registry of Older Patients With Cancer | recruiting | — | 3,000 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT02012699 | Integrated Cancer Repository for Cancer Research(iCaRe2) | recruiting | — | 999,999 | University of NebraskaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03571321 | Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia | recruiting | Phase 1 | 15 | University of ChicagoOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)(BMT-13) | recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT07671378 | A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients | recruiting | Phase 2 | 24 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04869683 | Biocollection in MyeloDysplastic Syndrome (P-MDS)(P-MDS) | recruiting | N/A | 150 | University Hospital, BrestOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06544785 | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | recruiting | Phase 2 | 106 | PETHEMA FoundationOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07575971 | Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 30 | Liping DouOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668557 | Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia(ICG415-AML-01) | recruiting | Phase 1 | 18 | iCell Gene TherapeuticsINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT06551584 | Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT | recruiting | Phase 1 | 24 | Stanford UniversityOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03670966 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT05549661 | Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms | recruiting | Phase 1 | 25 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05756777 | A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) | recruiting | Phase 1 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06017258 | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | recruiting | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07080970 | Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions(ACTIVATE) | recruiting | — | 220 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | recruiting | Phase 1 / Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06579469 | Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy | recruiting | — | 100 | St. Jude Children's Research HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06707493 | Ivosidenib as Post-HSCT Maintenance for AML | recruiting | Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Jul 6, 2026source: clinicaltrials